**Dear Editor,**

NDM-5, a variant of NDM, was first identified in 2011 in an *Escherichia coli* isolate from the perineum and the throat of a patient in the United Kingdom with a recent history of hospitalization in India.^[@bib1]^ Three years later, *E. coli* producing the same type of enzyme was isolated from urine and blood specimens of three Algerian patients as the first autochthonous cases of infection.^[@bib2]^ Just recently a NDM-5-producing *E. coli* isolate was also obtained from the urine of a Spanish patient with pyelonephritis who had no recent history of travelling or hospitalization.^[@bib3]^ Hereby, we characterize the first case of *E. coli* producing NDM-5, isolated from the ascitic fluid of a 52-year-old female patient with post-hepatitis cirrhosis admitted to Theodor Bilharz Research Institute, a tertiary care hospital in Egypt. The patient had fever, jaundice and massive ascites, and she did not have a travel history. The *E. coli* isolate was identified using Vitek2 system (bioMerieux, Marcy L\'Etoile, France) and was resistant to all β-lactams, including carbapenems. The minimum inhibitory concentration (MIC) of a set of antibiotics was determined by the broth microdilution method following the Clinical Laboratory Standards Institute (CLSI) guidelines.^[@bib4]^ The isolate showed resistance to ceftazidime, cefotaxime, imipenem, meropenem, ertapenem, gentamicin, tobramycin, ciprofloxacin and nalidixic acid, whereas the susceptibility to amikacin, tigecycline and colistin was retained ([Table 1](#tbl1){ref-type="table"}). The PCR and sequence analysis for carbapenemases, extended-spectrum *β*-lactamases (ESBLs), plasmid-mediated AmpC cephalosporinase-encoding genes, plasmid-mediated quinolone resistance genes, aminoglycoside-modifying enzymes and methyltransferases^[@bib5],\ [@bib6],\ [@bib7]^ identified the presence of *bla*~NDM-5~*, bla*~CTX-M-15~*, bla*~OXA-181~*, bla*~CMY-2~*, aac(3)-IIa* and *aac(6′)-Ib-cr*. PCR-based plasmid replicon typing detected the presence of two replicons, FIA and FIB.^[@bib6]^ Multilocus sequence typing (MLST), performed according to the Genotyping of Pathogens and Public Health (Institute Pasteur, Paris, France; <http://www.pateur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html>), identified the isolate as ST410, which is different from those in previously reported cases of NDM-5, which were ST648 and ST2659 and was infrequently encountered in North Africa.^[@bib8]^ Whereas an association between ST410 and NDM-1 has been reported in Norway, the United Kingdom, Switzerland, France and the United States, more recently, it was found in Poland in a patient who had previously received care in Tunisia after a terrorist attack.^[@bib8],\ [@bib9]^ To the best of our knowledge, this is the first report of ST410 in Egypt. The genetic environment of *bla*~NDM-5~, assessed by PCR mapping as previously described,^[@bib10]^ showed 99% similarity to that of the plasmid pHC105 (accession number KM 598665.1), retaining the same gene arrangement (ΔIS*Aba125\_ bla*~NDM-5~\_*ble*~MBL~).^[@bib3]^

Conjugation experiments using the azide-resistant *E. coli* J53 as the recipient strain at two different temperatures and with plates containing meropenem at 0.5 μg/mL failed. Therefore, plasmid extraction using a QIAGEN Midi Kit (Qiagen, Hilden, Germany) followed by electrotransformation experiments into *E. coli* Top10 was performed.

The resistance phenotype and the gene content of the transformants were assessed and compared with those of the parental cells ([Table 1](#tbl1){ref-type="table"}).

Plasmid analysis by an S1 nuclease digestion of the whole genomic DNA followed by pulsed-field gel electrophoresis (S1-PFGE) showed that the isolate had three plasmids of sizes approximately 48.5, 88 and 100 kb. Southern blot hybridization of the S1-PFGE plasmid DNA was performed using a DIG DNA Labeling and Detection Kit (Roche, Mannheim, Germany) with DIG-labeled probes for *bla*~NDM-5~, *bla*~OXA-181~, *bla*~CTX-M-15~, FIA and FIB showing that the *bla*~NDM-5~ and *bla*~CTX-M-15~ were all located on the same plasmid (an ≈100 kb plasmid), in both the parental and the transformed cells, which were also collocated with FIA and FIB, indicating the presence of a multireplicon plasmid, whereas *bla*~OXA-181~ was found on another plasmid of size ≈48.5 kb only in the parental cell.

In Egypt, NDM-1 was first identified in 2013 in one *Klebsiella pneumoniae* isolate, and then more cases were found in Enterobacteriaceae, *Pseudomonas aeruginosa* and *Acinetobacter baumannii*.^[@bib11]^ By contrast, NDM-2 was previously reported in *A. baumannii* in 2011.^[@bib12]^ Compared with NDM-1, NDM-5 has two amino-acid substitutions (Val~88~→Leu) and (Met~154~→Leu), which confer enhanced hydrolytic activity against carbapenems.

Additionally, OXA-181, a variant of OXA-48, is associated with other carbapenemase genes, such as *bla*~NDM-1~ and *bla*~VIM-5~.^[@bib13]^ The co-production of OXA-181 with NDM-5 has been recently reported in *K. pneumoniae*;^[@bib14]^ however, the emergence of this co-existence in *E. coli* is alarming as it is believed that the worldwide spread of this enzyme is a mirror image to that of NDM-1.^[@bib13]^

We hereby report the first case of NDM-5 in Egypt, confirming the pervasiveness of the NDM enzymes in North Africa and the urgent need for public health concern towards the evolution and spread of these enzymes.
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###### MICs of different antibiotics in NDM-5-producing *E. coli* (donor), *E. coli* top10 (recipient), and derived transformants and resistance gene content in parental *E. coli* and the transformant cell

  **Isolate**        **MIC of antibiotics**   **Resistance gene content**                                                                                                      
  ----------------- ------------------------ ----------------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------------------------------------------------------------------------------------------------------
                            **CAZ**                     **CTX**             **IMP**   **MEM**   **ERT**   **AMK**   **GEN**   **TOB**   **CIP**   **NAL**   **TGC**   **CST**                                                      
  *E. coli*                  \>128                       \>128                16        64        128        4        128       64       \>128     \>128     0.125     0.125    *bla*~NDM-5~*, bla*~CTXM15~*, bla*~OXA-181~*, bla*~CMY-2~*, FIA, FIB, aac(6′)-Ib-cr, aac(3)-IIa, qnrS*
  *E. coli* Top10             0.25                       ⩽0.06               0.25      ⩽0.06     0.002       2        0.5       0.5      ⩽0.06       2       0.125     ⩽0.06                                                     ---
  Transformant               \>128                       \>128                 4         4         4         4        128       32       ⩽0.06       2       0.125     ⩽0.06                    *bla*~NDM-5~*, bla*~CTX-M-15~*, FIA, FIB, aac(6\')-Ib-cr, aac(3)-IIa*

Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; CTX, cefotaxime; ERT, ertapenem; GEN, gentamicin; IPM, imipenem; MEM, meropenem; NAL, nalidixic acid; TGC, tigecycline; TOB, tobramycin.
